articles details

From October 7 to 10, the 2025 NEALS Annual Meeting successfully concluded in Clearwater, Florida, USA. This year’s meeting focused on amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases, bringing together numerous experts from global academic institutions, clinical centers, pharmaceutical companies, biotechnology firms, and patient organizations. Discussions centered on topics such as advances in clinical research, trial design, biomarkers, real-world evidence, and therapeutic strategies.
 Darwincell Biotech was invited to attend and presented its latest research progress in ALS treatment through a poster presentation. The poster showcased our company’s findings on neural repair mechanisms based on stem cell stress-induction technology and related translational medicine data, and facilitated preliminary exchanges with attending experts.

About NEALS

The NEALS Annual Meeting is one of the most influential international academic platforms in the field of ALS research and clinical treatment. It emphasizes the integration of scientific research and clinical practice, as well as collaboration among patient communities and multiple stakeholders.
 Through thematic sessions, workshops, roundtable forums, and partnership discussions, the meeting builds a comprehensive international cooperation network that connects research, industry, clinical application, and regulation.

Presentation of ALT001

ALS is a rapidly progressive neurodegenerative disease with limited global treatment options, primarily relying on Riluzole and Edaravone. Patients typically have a survival period of only 3–5 years, highlighting the urgent need for new and effective therapies.
 ALT001, developed by Darwincell Biotech, is a novel neurorepair protein formulation derived from stem cell stress-induction technology.
 Preclinical studies have shown that ALT001 effectively enhances cell viability under oxidative stress, protects motor neurons, and significantly improves muscle atrophy, motor function, and survival in SOD1^G93A mouse models.

In a randomized, double-blind, placebo-controlled clinical trial conducted at Beijing Tiantan Hospital, most patients receiving ALT001 demonstrated positive therapeutic responses. After 120 days of treatment, patients exhibited clinically meaningful improvements in ALSFRS-R scores with a clear dose-response relationship. In addition, cerebrospinal fluid levels of neurofilament light chain (NfL) decreased in a dose-dependent manner, suggesting a potential neuroprotective effect. Some patients also showed signs of improved handwriting and motor function.

Through this poster presentation, Beijing Darwincell Biotech engaged in preliminary discussions and exchanges with multiple international researchers and clinical experts, providing valuable references for future studies.

Ms. Yu Wang, Founder of Beijing Darwincell Biotech, stated: “We sincerely appreciate NEALS for providing this opportunity for exchange and learning. We will continue to advance the development of new therapies for ALS and other neurodegenerative diseases driven by clinical needs, strengthen collaboration with leading international research institutions and experts, and strive to deliver safer and more effective treatment options for patients worldwide.”

Looking Ahead

The NEALS Annual Meeting brought significant international visibility and collaboration opportunities for Darwincell Biotech.
 Going forward, we will uphold its R&D philosophy of “science-driven and patient-centered,” accelerate the clinical translation and industrialization of its ALS cell-based therapeutic products, and continue to collaborate with domestic and international institutions, clinical experts, and industry partners to jointly promote innovation and progress in the field of neurodegenerative diseases.

‍